CLPTM1L Knockout Raji Polyclonal Cells

Product Type:
Polyclonal Cell Population
Species:
Homo sapiens (Human)
Tissue Source:
Bone
Disease:
Burkitt lymphoma

Datasheet

The CLPTM1L Knockout Raji Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout population in Raji B lymphocytes, targeting the apoptosis regulator and cisplatin resistance factor CLPTM1L. Disruption of this transmembrane protein impairs PI3K/AKT signaling, downregulates BCL-2 family anti-apoptotic proteins, and facilitates caspase-3 activation, thereby sensitizing cells to DNA-damaging agents. This model is ideal for studying molecular mechanisms of chemoresistance in Burkitt's lymphoma. Applications include investigation of DNA damage response pathways, high-throughput screening for cisplatin sensitizers, and dissection of CLPTM1L-dependent signaling in B-cell malignancies. Key downstream effectors such as AKT, phospho-AKT, and BCL-2 can be monitored via western blotting or flow cytometry-based apoptosis assays. For further technical details, contact Ascent Research.

Inquire Now

In stock

Ships next business day

Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice

Disclaimer:

For Research Use Only

Characteristics

Host Cell

Raji

Cell Type

B cell line

Sex of Donor

Male

Age

11 years

Derived From Site

In situ; Maxilla

Gene Name

CLPTM1L

Gene Identifier

NCBI Gene ID 81037

Morphology

Lymphoblast-like

Growth Mode

Suspension

Storage

Liquid nitrogen (LN2)
Culture Conditions

Growth medium

RPMI 1640

Supplement(s)

10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

Temperature

37°C

Atmosphere

5% CO₂
Quality Control

Sterility testing

The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Mycoplasma testing

Negative for mycoplasma through PCR analysis
Disclaimer

Intended Use

This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

Disclaimer

Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

This product consists of CRISPR/Cas9-edited polyclonal knockout cell populations targeting the CLPTM1L gene in the Raji B lymphocyte line.

These polyclonal cells harbor a heterogeneous ensemble of gene disruptions introduced by non-homologous end joining, providing a robust loss-of-function model without clonal selection.

The polyclonal format retains cellular diversity, reducing clone-specific biases and better reflecting the genetic heterogeneity inherent to tumor cell populations.

This knockout model is designed to eliminate functional CLPTM1L protein expression, enabling researchers to dissect the protein’s contributions to cell survival, apoptosis regulation, and drug resistance.